Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...